Expression and function of TRAIL (TNF-related apoptosis-inducing ligand) and its death receptors on human iNKT cells

被引：0
|
作者：
Ayyildiz, Zeynep Ozge [1 ]
Wingender, Gerhard [2 ]
机构：
[1] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst, Izmir, Turkey
[2] Izmir Biomed & Genome Ctr IBG, Izmir, Turkey
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2021年 / 51卷
关键词：
Cell death; cytokines and mediators; effector molecules; NKT cells;
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P-0091
引用
收藏
页码：151 / 151
页数：1
相关论文
共 25 条
  • [21] Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics
    Maji, Avik
    Paul, Abhik
    Sarkar, Arnab
    Nahar, Sourin
    Bhowmik, Rudranil
    Samanta, Ajeya
    Nahata, Pankaj
    Ghosh, Balaram
    Karmakar, Sanmoy
    Maity, Tapan Kumar
    BIOCHEMICAL PHARMACOLOGY, 2024, 221
  • [22] Fetal-derived trophoblast use the apoptotic cytokine tumor necrosis factor-α-related apoptosis-inducing ligand to induce smooth muscle cell death
    Keogh, Rosemary J.
    Harris, Lynda K.
    Freeman, Abigail
    Baker, Philip N.
    Aplin, John D.
    Whitley, Guy Stj.
    Cartwright, Judith E.
    CIRCULATION RESEARCH, 2007, 100 (06) : 834 - 841
  • [23] Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein-induced Lysosomal Translocation of Proapoptotic Effectors Is Mediated by Phosphofurin Acidic Cluster Sorting Protein-2 (PACS-2)
    Werneburg, Nathan W.
    Bronk, Steve F.
    Guicciardi, Maria Eugenia
    Thomas, Laurel
    Dikeakos, Jimmy D.
    Thomas, Gary
    Gores, Gregory J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (29) : 24427 - 24437
  • [24] The death-promoting molecule tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is not required for the development of peripheral lymphopenia or granuloma necrosis during infection with virulent Mycobacterium avium
    Borges, M.
    Rosa, G. T.
    Appelberg, R.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 164 (03) : 407 - 416
  • [25] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    Trarbach, T.
    Moehler, M.
    Heinemann, V.
    Koehne, C-H
    Przyborek, M.
    Schulz, C.
    Sneller, V.
    Gallant, G.
    Kanzler, S.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 506 - 512
123